ãã€ãªå»è¬åäŒç€Ÿã§ãã Vanda Pharmaceuticals Inc. ã¯ãæºããããŠããªãé«ãå»çããŒãºã«å¯Ÿå¿ããæ²»çæ³ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®åžè²©è£œåã«ã¯ãé 24 æéç¡ç èŠééå®³ã®æ²»çè¬ HETLIOZãçµ±å倱調çã®æ²»çè¬ Fanapt çµå£é ãªã©ããããŸããéçºäžã®è£œåã«ã¯ãæå·®ãŒãé害ãã¹ãã¹ã»ããžã§ãã¹çå矀ãå°å
é 24 æéç¡ç ãèªéçã¹ãã¯ãã©ã ãç¡ç çžåŸééå®³ã®æ²»çè¬ HETLIOZ (ã¿ã·ã¡ã«ããªã³)ã忥µæ§éå®³ã®æ²»çè¬ Fanapt (ã€ãããªãã³)ãçµ±å倱調çã®æ²»çè¬ã®é·æéäœçšå泚å°å€ããã°ã©ã ãã¢ãããŒæ§ç®èçãèäžå
šéº»çºãä¹ãç©é
ãã®æ²»çè¬ã§ããå°ååãã¥ãŒãããã³ 1 åå®¹äœ (NK-1R) æ®æè¬ Tradipitant (VLY-686) ãªã©ããããŸããå瀟ã®éçºäžã®è£œåã«ã¯ãè¡æ¶²æªæ§è
«çã®æ²»çããã³ããŸããŸãªè
«çåŠçé©å¿çã®æ²»çè¬ãšããŠã®å¯èœæ§ãæã€äœååãã¹ãã³è±ã¢ã»ãã«åé
µçŽ é»å®³å€ VTR-297ã粟ç¥çŸæ£ã®æ²»çãç®çãšããäœååãã³ãã³æ§ã¢ã»ãã«ã³ãªã³å容äœéšåäœåè¬ VQW-765ããã©ã€ã¢ã€ããã³çŒçã®æ²»çãç®çãšããå¢èæ§ç·ç¶çèã³ã³ãã¯ã¿ã³ã¹èª¿ç¯å åæŽ»æ§åå åããã³é»å®³å€ã®ããŒããã©ãªãªãããã³ã³ã¬ã©ãå«ãåæ³æ§äžç¢æ§çŸæ£ã®æ²»çãç®çãšãã BPO-27 ãªã©ããããŸããå瀟ã¯ç±³åœããšãŒããããã€ã¹ã©ãšã«ã§è£œåã販売ããŠããŸããVanda Pharmaceuticals Inc. 㯠2002 幎ã«èšç«ãããã¯ã·ã³ãã³ D.C. ã«æ¬ç€Ÿã眮ããŠããŸãã